Clinical trials: With
Burns
ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries
This is a randomized, within-subject controlled study to compare the clinical performance of the ReCell device when used as an adjunct to meshed skin graft in subjects requiring skin grafts for closure of burn injuries.
- Trial name
- NCT02380612
- Testing
- ReCell Treatment, Skin Graft
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Avita Medical
Atopic Dermatitis
Evaluation of the Efficacy of Topialyse Baume barrière on Atopic Dermatis
The purpose of this study is to evaluate the efficacy and tolerability of a new SVR care product and to evaluate the reduction of the topical corticosteroids' consumption with this emollient care.
- Trial name
- TOPIA (NCT05006300)
- Testing
- Topialyse Baume Barrière
- Sponsor
- SVR Group
Hepatitis C Virus (HCV)
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.
- Trial name
- NCT03341871
- Where
- Japan
- Volunteers
- 1,095 people
- Sponsor
- AbbVie
Asthma
Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
Effectiveness of adding montelukast to inhaled corticosteroids in adult subjects with both uncontrolled asthma and allergic rhinitis.
- Trial name
- NCT00545844
- Testing
- montelukast sodium
- Volunteers
- 313 people
- Sponsor
- Organon and Co
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17
- Trial name
- NCT00152009
- Testing
- SPD503 (Guanfacine hydrochloride) (2 mg), SPD503 (3 mg), SPD503 (4 mg)
- Volunteers
- 345 people
- Sponsor
- Shire
Diabetes, Diabetes Mellitus, Type 1 Diabetes
Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device
The purpose of this study is to collect information about Fiasp® to evaluate how effective Fiasp® is in treating elevated blood sugar in patients with type 1 diabetes, compared with the participant's previous insulin treatment.
- Trial name
- GoBolus (NCT03450863)
- Testing
- Fast-acting insulin aspart
- Where
- Germany
- Volunteers
- 320 people
- Sponsor
- Novo Nordisk A/S
Osteonecrosis of Femoral Head
The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH)
The purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating osteonecrosis of femoral head patients.
- Trial name
- NCT03180463
- Testing
- Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), core decompression
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Clostridium Difficile-associated Diarrhea
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of fidaxomicin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- NCT01591863
- Testing
- fidaxomicin
- Volunteers
- 38 people
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Rheumatoid Arthritis
Safety and Efficacy of AMG 827 in Subjects With RA
This is an extension study for subjects who participated in Protocol 20090061 (NCT00950989). All subjects in this study will receive a 210mg injection of AMG827 for treatment for their Rheumatoid Arthritis for up to 5 years.
- Trial name
- NCT01059448
- Testing
- AMG 827
- Where
- 44 sites in United States, Bulgaria and 6 more
- Volunteers
- 211 people
- Sponsor
- Amgen
Nasopharyngeal Neoplasms, Carcinoma
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma…
- Trial name
- NCT00565448
- Testing
- docetaxel, cisplatin, 5-fluorouracil
- Where
- 26 sites in Algeria, Brazil and 12 more
- Volunteers
- 75 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Special Survey for Patients With Type 1 or Type 2 Diabetes
This study is conducted in Japan. The aim of this study is to evaluate the incidence of severe hypoglycaemia under normal clinical practice.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01538589
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 1,582 people
- Sponsor
- Novo Nordisk A/S
Acute Myelocytic Leukemia
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD123 in the treatment of Acute Myelocytic Leukemia.
- Trial name
- NCT03796390
- Testing
- CD123 CAR-T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Sickle Cell Disease
Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease
- Trial name
- GBT_HOPE (NCT03036813)
- Testing
- voxelotor
- Where
- 62 sites in United States, Canada and 10 more
- Volunteers
- 449 people
- Sponsor
- Pfizer
Chondral Defect, Articular Cartilage Defect
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with…
- Trial name
- MASCOT (NCT06915233)
- Testing
- autologous cultured chondrocytes on porcine collagen membrane, Bone Marrow Stimulation
- Where
- 9 sites in United States
- Volunteers
- 309 people
- Sponsor
- Vericel Corporation
ADHD
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
This study is a multicenter, dose-optimized, open-label safety study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03460652
- Testing
- KP415 oral capsule
- Where
- 19 sites in United States
- Volunteers
- 282 people
- Sponsor
- Zevra Therapeutics
Acute Malaria
Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
The purpose of this study was to evaluate the safety, efficacy, and pharmacokinetic of the combination M5717 plus pyronaridine in participants with acute uncomplicated Plasmodium falciparum malaria.
- Trial name
- NCT05689047
- Testing
- M5717 330 mg, M5717 500 mg, M5717 660 mg
- Where
- 5 sites in Burkina Faso, Gabon and 2 more
- Volunteers
- 38 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Asthma
Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174733
- Testing
- Ciclesonide (XRP1526)
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- Sanofi
Sickle Cell Disease
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy
This is a multi-center, long-term safety and efficacy follow-up study for subjects with sickle cell disease who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored clinical studies.
- Trial name
- NCT04628585
- Testing
- Safety and efficacy assessments
- Where
- 16 sites in United States, France
- Volunteers
- 85 people
- Sponsor
- Genetix Biotherapeutics Inc.
Growth Disorders
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
This is an extension study to Tercica study MS301 (NCT00125164) and is intended to collect long term safety and efficacy data on the continued use of recombinant human insulin-like growth factor-1 (rh IGF-1) in children and…
- Trial name
- NCT00330668
- Testing
- rh IGF-1 (mecasermin)
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Ipsen
Attention Deficit Disorder With Hyperactivity
An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, tolerability and effects of Osmotic Release Oral System (OROS) methylphenidate hydrochloride (HCl) on learning skill changes in Korean participants with Attention-Deficit…
- Trial name
- NCT01060150
- Testing
- OROS Methylphenidate HCl
- Volunteers
- 115 people
- Sponsor
- Janssen Korea, Ltd., Korea
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.